Biblio Discovery — Demo Discovery Service

14 hasil untuk "Drew Provan"

Menampilkan 1–14 · 0,17 detik · RSS

  1. Artikel Jurnal

    Recent advances in the mechanisms and treatment of immune thrombocytopenia

    Drew Provan; John W. Semple

    EBioMedicine, Vol. 76 · 2022 · Inggris · DOAJ Scopus

    Summary: Primary immune thrombocytopenia is an autoimmune disease associated with a reduced peripheral blood platelet count. The phenotype is variable with some patients suffering no bleeding whilst others have severe bleeding which may be fatal. Variability in clinical behaviour and treatment…

  2. Artikel Jurnal Teks lengkap

    Sustained Remission Off-Treatment (SROT) of TPO-RAs: The Burgos Ten-Step Eltrombopag Tapering Scheme

    Tomás José González-López; Drew Provan

    Medicina, Vol. 59 No. 4 · 2023 · Inggris · DOAJ Scopus

    Background and Objectives: TPO-RAs (romiplostim/eltrombopag/avatrombopag) have broadly demonstrated high efficacy rates (59–88%), durable responses (up to three years) and a satisfactory safety profile in clinical trials. The effect of TPO-RAs is classically considered to be transient because…

  3. Artikel Jurnal Teks lengkap

    Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View

    Tomás José González-López; Adrian Newland; Drew Provan

    Medicina, Vol. 59 No. 4 · 2023 · Inggris · DOAJ Scopus

    Primary immune thrombocytopenia (ITP) is an acquired blood disorder that causes a reduction in circulating platelets with the potential for bleeding. The incidence of ITP is slightly higher in adults and affects more women than men until 60 years, when males are more affected. Despite advances in…

  4. Artikel Jurnal

    Immune thrombocytopenia: Modern management, knowledge gaps, and future perspectives

    Waleed Ghanima; Lamya Garabet; Rick Kapur dkk.

    Iraqi Journal of Hematology, Vol. 14 No. 2 · 2025 · Inggris · DOAJ Scopus

    Immune thrombocytopenia (ITP) is an autoimmune disorder with increased risk of bleeding due to a low number of platelets. The pathophysiology is complex and not fully understood, but platelet autoantibodies and/or CD8+ T-cells are responsible, via diverse mechanisms, for disrupting platelet…

  5. Artikel Jurnal Teks lengkap

    Can Machine Learning Assist in Diagnosis of Primary Immune Thrombocytopenia? A Feasibility Study

    Haroon Miah; Dimitrios Kollias; Giacinto Luca Pedone dkk.

    Diagnostics, Vol. 14 No. 13 · 2024 · Inggris · DOAJ Scopus

    Primary Immune Thrombocytopenia (ITP) is a rare autoimmune disease characterised by the immune-mediated destruction of peripheral blood platelets in patients leading to low platelet counts and bleeding. The diagnosis and effective management of ITP are challenging because there is no established…

  6. Artikel Jurnal

    Literature Review and Experts’ Opinion for Managing Thrombocytopenia in Chronic Liver Disease

    Faisal Alsayegh; Ahmed Alfadhli; Abeer Algharabally dkk.

    Journal of Applied Hematology, Vol. 16 No. 1 · 2025 · Inggris · DOAJ Scopus

    Thrombocytopenia (TCP) commonly complicates chronic liver disease (CLD), with platelet transfusion traditionally serving as the standard therapeutic approach, despite associated risks such as infection, alloimmunization, and transfusion reactions. Recent advancements have introduced thrombopoietin…

  7. Artikel Jurnal

    Inflammatory cytokines, inflammasomes, and neutrophil extracellular traps in primary immune thrombocytopenia pathogenesis

    Alessandro Lucchesi; Maria Belen Rodriguez; Matias Cordoba dkk.

    Blood Vessels, Thrombosis & Hemostasis, Vol. 3 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract: Primary immune thrombocytopenia (ITP) is a disorder characterized by enhanced platelet clearance and impaired production due to immune dysregulation. Central to its pathogenesis are platelet autoantibodies, T-cell–mediated processes, and altered cytokine profiles, which exacerbate…

  8. Artikel Jurnal

    Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently

    Mohamed A. Yassin; Mona Al-Rasheed; Murtadha Al-Khaboori dkk.

    Frontiers in Cardiovascular Medicine, Vol. 10 · 2023 · Inggris · DOAJ Scopus

    IntroductionThrombopoietin-receptor agonist (TPO-RAs) currently represent the state of art for treating immune thrombocytopenia. Their different molecular structures contribute to the difference in their pharmacodynamics and pharmacokinetics. This narrative review aims to provide an overview of the…

  9. Artikel Jurnal

    Concurrent coronary artery disease and immune thrombocytopenia: a systematic review

    Alaa Rahhal; Drew Provan; Khaled Shunnar dkk.

    Frontiers in Medicine, Vol. 10 · 2023 · Inggris · DOAJ Scopus

    IntroductionCoronary artery disease (CAD) management in the setting of immune thrombocytopenia (ITP) remains very challenging to clinicians as a reasonable balance between bleeding and thrombosis risks needs to be achieved, and the evidence guiding such management is scarce.MethodsWe conducted a…

  10. Artikel Jurnal

    A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome

    Alaa Rahhal; Drew Provan; Waleed Ghanima dkk.

    Frontiers in Medicine, Vol. 11 · 2024 · Inggris · DOAJ Scopus

    IntroductionImmune thrombocytopenia (ITP) management with co-existing acute coronary syndrome (ACS) remains challenging as it requires a clinically relevant balance between the risk and outcomes of thrombosis and the risk of bleeding. However, the literature evaluating the treatment approaches in…

  11. Artikel Jurnal

    Iraqi consensus recommendations for the diagnosis and management of immune thrombocytopenia

    Ahmed Mjali; Bassam Francis Matti; Waleed Ghanima dkk.

    Hematology, Vol. 30 No. 1 · 2025 · Inggris · DOAJ Scopus

    Background and Objectives The management of ITP has evolved with evidence-based international guidelines. However, Iraq’s unique challenges, including variations in clinical practice and treatment disparities, necessitate localized guidance to bridge global recommendations and real-world practice…

  12. Artikel Jurnal

    Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques

    Tomás José González-López; Ricardo Sanchez; Carmen Pastoriza dkk.

    Blood Vessels, Thrombosis & Hemostasis, Vol. 2 No. 3 · 2025 · Inggris · DOAJ Scopus

    Abstract: Thrombopoietin receptor agonists, for example eltrombopag, are standard second-line treatment for immune thrombocytopenia (ITP). Eltrombopag has demonstrated high response rates, both in clinical trials and in routine practice studies. However, some patients with ITP are refractory to…